Qure NV (QURE) reports significant progress in Huntington's disease treatment but faces hurdles with FDA approval.

Management stated that the timing of the BLA submission for AMT-130 is now uncertain following recent FDA feedback. Kapusta explained, "the latest FDA feedback is certainly surprising and ...

Three years ago, when Tris Dyson was first diagnosed with amyotrophic lateral sclerosis (ALS), better known as motor neurone ...

Amylyx Pharmaceuticals Inc (AMLX) reports a robust cash position and advances in its lead program, despite challenges in trial timelines.

The progressive loss of neuronal structure and function in disorders such as Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), ...

Neurodegenerative diseases such as such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) represent major ...

Q3 2025 Management View Justin Klee, Co-Founder, Co-CEO & Director, announced "Q3 was a quarter of progress as we continue to focus on our lead program, avexitide, in post-bariatric hypoglycemia or ...

Amryta’s Sodesta gene therapy gains accelerated approval for ALS The Food and Drug Administration has granted accelerated ...

SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.

Researchers developed a cell-free DNA blood test that accurately distinguishes ALS from other neurological diseases and tracks progression.

Although amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). are very different diseases, they have ...

A year after Neuralink secured FDA approval to test brain implants designed to restore sight, one of its earliest patients has found another use for the ...